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Abstract: Enteroviruses cause various acute and chronic diseases. The most promising therapeutics for 
these infections are capsid-binding molecules. These can act against a broad spectrum of 
enteroviruses, but emerging resistant virus variants threaten their efficacy. All known enterovirus 
variants with high-level resistance toward capsid-binding molecules have mutations of residues 
directly involved in the formation of the hydrophobic binding site. This is a first report of substitutions 
outside the binding pocket causing this type of drug resistance: I1207K and I1207R of the viral capsid 
protein 1 of coxsackievirus B3. Both substitutions completely abolish the antiviral activity of pleconaril 
(a capsid-binding molecule) but do not affect viral replication rates in vitro. Molecular dynamics 
simulations indicate that the resistance mechanism is mediated by a conformational rearrangement of 
R1095, which is a neighboring residue of 1207 located at the heel of the binding pocket. These insights 
provide a basis for the design of resistance-breaking inhibitors. 
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Dear Professor Vasudevan, 
 
please find enclosed the revised version of our manuscript "Molecular mechanism of a 
specific capsid binder resistance caused by mutations outside the binding pocket”. 
 
We thank both reviewers for the very constructive comments, which helped us to 
substantially improve the manuscript. In this revised version we believe that we were able to 
address all comments and concerns raised by the Reviewers. 
Below you will find a point-by-point response to the Editor’s and Reviewer’s comments. 
 
We hope that you will enjoy this revised version of our manuscript and look forward to your 
reply. 
 
Kind regards, 
  Michaela Schmidtke 
 
Cover Letter
Answers (normal) to Reviewers' comments (in bold):  
Reviewer #1: The manuscript authored by Braun and colleagues reports the molecular 
characterization of two pleconaril mutants bearing amino acid substitutions at 
position 1207 of the viral capsid protein 1 of coxsackie virus B3. Resistance to 
pleconaril (a capsid-binding inhibitor, CI) has been previously reported to be linked to 
mutations in the hydrophobic drug binding pocket. Interestingly, residue 1207 is not 
part of the binding pocket and therefore is not in direct interaction with pleconaril. 
The findings of this study are interesting but the biological characterization of the 
1207 viral capsid protein 1 mutants is not complete. It appears to be an imbalance 
between the detailed molecular characterizations of the effects of these two mutations 
compared to the virological properties of the mutants. The authors should address the 
following points: 
- Figure 2 (appears before Figure 1).  
We corrected this.  
The same moi (10 PFU/cell) for the different viruses was used to infect HeLa cell 
cultures. It appears that the virus detected at 1 h post-infection differs (more than 1 
log) among the viral strains? Were the cultures used at different stages of confluence? 
This assumption is incorrect. To confirm this, we added Table S2 in the Supplementary 
Information that indicates for the wildtype virus as well as all three resistant variants the 
determined virus titers. As suggested by the reviewer (see answer below), we also 
performed a statistical analysis (Mann-Whitney-U-test; last sentence in 2.6). No statistically 
significant differences could be found. We have added a statement to the manuscript text: 
“Furthermore, no significant difference was detected with the Mann-Whitney-U test, 
comparing single-step growth curves of wt-CVB3 97927 and high-level resistant variants in 
HeLa cells (Figure 2B; Table S2).” 
 
If there is no difference in the kinetics of replication between the different viruses, why 
are more antigen positive cells in the variant 1 (M1092 - I1027) than in the wild-type 
and the two I1207 mutants? 
Yes, there are more antigen-positive cells in the HR variant 1. We confirmed the virus titer 
used for MOI calculation and repeated the experiment. Here, similar results were obtained. 
Furthermore, we would like to mention that immunohistochemical staining was mainly used 
to confirm the results of plaque reduction assays which showed that even a high 
concentration of pleconaril (which nearly completely prevented CVB3 97927 wt replication) 
does not act against the HR variants.  
In addition, these results underline that the HR variant is not hampered in fitness compared 
to CVB3 97927 wt.  
 
The single-step growth curves are not statistically analyzed to affirm that there was no 
significant difference between them. 
According to the reviewer´s suggestion statistical analysis (Mann-Whitney-U-test) was 
performed. No statistical difference was observed. These results further confirm our 
conclusion. They are reported in the manuscript text: “Furthermore, no significant difference 
was detected with the Mann-Whitney-U test, comparing single-step growth curves of wt-
CVB3 97927 and high-level resistant variants in HeLa cells (Figure 2B; Table S2).” 
- There is no report on the fold resistance obtained for the different mutants against 
pleconaril. Table 1 does not provide and EC50 or EC90 for the diverse mutants 
compared to the wild-type virus. It is necessary to report the level of resistance 
conferred by a mutation in the hydrophobic drug binding protein (I1092M) versus the 
mutations I1207K and I1207R outside the binding pocket. 
We fully agree with the reviewer, but, pleconaril did not act at non-cytotoxic concentrations in 
cytopathic effect inhibition assays performed with the three HR CVB3 97927 variants in HeLa 
cells. Therefore, EC50 or EC90 values cannot be provided. In contrast, pleconaril acted well 
against the wildtype virus. We added this information in Table 1 and also report the results 
from the cytopathic effect inhibition assay in the MM section, paragraph 2.4.: “For all nine 
purified isolates high-level resistance was confirmed in plaque reduction assays with 8 µg/ml 
of pleconaril (inactive) and in cytopathic effect inhibition assays for selected variants (one per 
mutation; Table 1).”  
 
- It is not clear how the frequency of pleconaril resistance in the wild-type population 
was calculated. 
The frequency of pleconaril resistance was calculated as described previously for other 
capsid inhibitors by Heinze et al. in J Virol. 1989. Accordingly, the frequency of survivors 
resistant to 1 µf/ml of pleconaril was determined. The methodical details of the used plaque 
reduction assay are described in MM section paragraph 2.4. 
- The authors discuss about high-resistance to pleconaril but there is no definition of 
resistance. What is the definition of high-resistance? 
This discussion is based on the HR definition of Heinze et al. in J Virol 1989: “…drug-
selected plaque isolates exhibited roughly the same infectivity titer in the presence of drug as 
in the absence”. In our study, pleconaril did neither inhibit plaque reduction nor acted in 
cytopathic effect inhibition assay at the highest non-cytotoxic concentration (50% cytotoxic 
concentration in HeLa cells: 12.5 µg/ml as described in Makarov et al. JAC 2005) against the 
resistant variants. In contrast, plaque production as well as CPE of CVB3 97927 wt were 
strongly inhibited. We added the results of CPE inhibition assays in Table 1 and mention as 
well the cytopathic effect inhibition assay in the MM section, paragraph 2.4. 
 
- The M&M for some of the virological experiments (e.g. viral protein expression and 
plaque reduction assay) should be better described. 
Unfortunately, there is a 3500 words limit. Therefore, we decided to refer to the already in 
detail published methods and describe only the modification e.g. plaque number and MOIs. 
The plaque reduction as well as CPE inhibition assay were published by us in J Virol 
Methods in 2001 and the detection of CVB3 by immunohistochemical staining in J Virol in 
2006. 
 
- English language should be revised. 
We have carefully revised the manuscript and believe that we were able to resolve the 
language issues. 
 
 
Reviewer #2: The manuscript from Brown et al. reports on some studies on CVB3 
resistance to the capsid inhibitor pleconaril. The paper is generally well written and 
provides some interesting data. However, I believe the quality of the manuscript could 
be improved with some modifications: 
 
The modelling section needs some improvements, in particular: 
 
It would be extremely useful to perform the molecular dynamics of the unbound 
proteins (wt and resistant proteins), as these could provide some important 
information regarding the activity of the compound. Indeed, it is entirely possible that 
the mutation will induce a conformational change in the protein that completely 
prevent binding of pleconaril. This aspect cannot really be explored only with the MD 
simulation presented in the paper. The overall discussion of the mechanism of 
resistance should be revisited based on the result of these new simulations. 
This is indeed an important point. We have simulated these three apo systems (wt, I1207K 
and I1207R) to investigate whether any significant changes to the conformation of the 
relevant protein region can be observed. Much to our own surprise the wt and mutated apo 
systems behaved very similar. No significant differences could be observed. This strongly 
indicates that the binding of pleconaril is not impaired by conformational changes of the 
unbound capsid protein. 
We emphasize these aspects in the revised version of the manuscript and have also added 
two new figures (now Figure 3A and 3B) that visualize the stability of the apo systems (and, 
specifically, the ligand binding pocket). 
 
The homology modelling methodologies need to be more detailed. More informational 
need on the "manual" changes introduced in the structures. 
Indeed, this was not explained adequately in the initial version of the manuscript. A detailed 
protocol was added to Section 2.7 of the Supporting Information. In brief: Schrodinger’s 
software Maestro includes a “Mutate Residue” function. Using this function, we individually 
mutated all non-conserved residues (these are only a few). This is a reproducible process 
without a random element. The conformations of the individual amino acids were then 
optimized during several steps of energy minimization and the initial 10 ns of molecular 
dynamics simulations, which were not used for analysis. 
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We thank both reviewers for the very constructive comments, which helped us to 
substantially improve the manuscript. In this revised version we believe that we were able to 
address all comments and concerns raised by the Reviewers. 
Below you will find a point-by-point response to the Editor’s and Reviewer’s comments. 
 
We hope that you will enjoy this revised version of our manuscript and look forward to your 
reply. 
 
Kind regards, 
  Michaela Schmidtke 
 
*Response to Reviewers
Answers (normal) to Reviewers' comments (in bold):  
Reviewer #1: The manuscript authored by Braun and colleagues reports the molecular 
characterization of two pleconaril mutants bearing amino acid substitutions at 
position 1207 of the viral capsid protein 1 of coxsackie virus B3. Resistance to 
pleconaril (a capsid-binding inhibitor, CI) has been previously reported to be linked to 
mutations in the hydrophobic drug binding pocket. Interestingly, residue 1207 is not 
part of the binding pocket and therefore is not in direct interaction with pleconaril. 
The findings of this study are interesting but the biological characterization of the 
1207 viral capsid protein 1 mutants is not complete. It appears to be an imbalance 
between the detailed molecular characterizations of the effects of these two mutations 
compared to the virological properties of the mutants. The authors should address the 
following points: 
- Figure 2 (appears before Figure 1).  
We corrected this.  
The same moi (10 PFU/cell) for the different viruses was used to infect HeLa cell 
cultures. It appears that the virus detected at 1 h post-infection differs (more than 1 
log) among the viral strains? Were the cultures used at different stages of confluence? 
This assumption is incorrect. To confirm this, we added Table S2 in the Supplementary 
Information that indicates for the wildtype virus as well as all three resistant variants the 
determined virus titers. As suggested by the reviewer (see answer below), we also 
performed a statistical analysis (Mann-Whitney-U-test; last sentence in 2.6). No statistically 
significant differences could be found. We have added a statement to the manuscript text: 
“Furthermore, no significant difference was detected with the Mann-Whitney-U test, 
comparing single-step growth curves of wt-CVB3 97927 and high-level resistant variants in 
HeLa cells (Figure 2B; Table S2).” 
 
If there is no difference in the kinetics of replication between the different viruses, why 
are more antigen positive cells in the variant 1 (M1092 - I1027) than in the wild-type 
and the two I1207 mutants? 
Yes, there are more antigen-positive cells in the HR variant 1. We confirmed the virus titer 
used for MOI calculation and repeated the experiment. Here, similar results were obtained. 
Furthermore, we would like to mention that immunohistochemical staining was mainly used 
to confirm the results of plaque reduction assays which showed that even a high 
concentration of pleconaril (which nearly completely prevented CVB3 97927 wt replication) 
does not act against the HR variants.  
In addition, these results underline that the HR variant is not hampered in fitness compared 
to CVB3 97927 wt.  
 
The single-step growth curves are not statistically analyzed to affirm that there was no 
significant difference between them. 
According to the reviewer´s suggestion statistical analysis (Mann-Whitney-U-test) was 
performed. No statistical difference was observed. These results further confirm our 
conclusion. They are reported in the manuscript text: “Furthermore, no significant difference 
was detected with the Mann-Whitney-U test, comparing single-step growth curves of wt-
CVB3 97927 and high-level resistant variants in HeLa cells (Figure 2B; Table S2).” 
- There is no report on the fold resistance obtained for the different mutants against 
pleconaril. Table 1 does not provide and EC50 or EC90 for the diverse mutants 
compared to the wild-type virus. It is necessary to report the level of resistance 
conferred by a mutation in the hydrophobic drug binding protein (I1092M) versus the 
mutations I1207K and I1207R outside the binding pocket. 
We fully agree with the reviewer, but, pleconaril did not act at non-cytotoxic concentrations in 
cytopathic effect inhibition assays performed with the three HR CVB3 97927 variants in HeLa 
cells. Therefore, EC50 or EC90 values cannot be provided. In contrast, pleconaril acted well 
against the wildtype virus. We added this information in Table 1 and also report the results 
from the cytopathic effect inhibition assay in the MM section, paragraph 2.4.: “For all nine 
purified isolates high-level resistance was confirmed in plaque reduction assays with 8 µg/ml 
of pleconaril (inactive) and in cytopathic effect inhibition assays for selected variants (one per 
mutation; Table 1).”  
 
- It is not clear how the frequency of pleconaril resistance in the wild-type population 
was calculated. 
The frequency of pleconaril resistance was calculated as described previously for other 
capsid inhibitors by Heinze et al. in J Virol. 1989. Accordingly, the frequency of survivors 
resistant to 1 µf/ml of pleconaril was determined. The methodical details of the used plaque 
reduction assay are described in MM section paragraph 2.4. 
- The authors discuss about high-resistance to pleconaril but there is no definition of 
resistance. What is the definition of high-resistance? 
This discussion is based on the HR definition of Heinze et al. in J Virol 1989: “…drug-
selected plaque isolates exhibited roughly the same infectivity titer in the presence of drug as 
in the absence”. In our study, pleconaril did neither inhibit plaque reduction nor acted in 
cytopathic effect inhibition assay at the highest non-cytotoxic concentration (50% cytotoxic 
concentration in HeLa cells: 12.5 µg/ml as described in Makarov et al. JAC 2005) against the 
resistant variants. In contrast, plaque production as well as CPE of CVB3 97927 wt were 
strongly inhibited. We added the results of CPE inhibition assays in Table 1 and mention as 
well the cytopathic effect inhibition assay in the MM section, paragraph 2.4. 
 
- The M&M for some of the virological experiments (e.g. viral protein expression and 
plaque reduction assay) should be better described. 
Unfortunately, there is a 3500 words limit. Therefore, we decided to refer to the already in 
detail published methods and describe only the modification e.g. plaque number and MOIs. 
The plaque reduction as well as CPE inhibition assay were published by us in J Virol 
Methods in 2001 and the detection of CVB3 by immunohistochemical staining in J Virol in 
2006. 
 
- English language should be revised. 
We have carefully revised the manuscript and believe that we were able to resolve the 
language issues. 
 
 
Reviewer #2: The manuscript from Brown et al. reports on some studies on CVB3 
resistance to the capsid inhibitor pleconaril. The paper is generally well written and 
provides some interesting data. However, I believe the quality of the manuscript could 
be improved with some modifications: 
 
The modelling section needs some improvements, in particular: 
 
It would be extremely useful to perform the molecular dynamics of the unbound 
proteins (wt and resistant proteins), as these could provide some important 
information regarding the activity of the compound. Indeed, it is entirely possible that 
the mutation will induce a conformational change in the protein that completely 
prevent binding of pleconaril. This aspect cannot really be explored only with the MD 
simulation presented in the paper. The overall discussion of the mechanism of 
resistance should be revisited based on the result of these new simulations. 
This is indeed an important point. We have simulated these three apo systems (wt, I1207K 
and I1207R) to investigate whether any significant changes to the conformation of the 
relevant protein region can be observed. Much to our own surprise the wt and mutated apo 
systems behaved very similar. No significant differences could be observed. This strongly 
indicates that the binding of pleconaril is not impaired by conformational changes of the 
unbound capsid protein. 
We emphasize these aspects in the revised version of the manuscript and have also added 
two new figures (now Figure 3A and 3B) that visualize the stability of the apo systems (and, 
specifically, the ligand binding pocket). 
 
The homology modelling methodologies need to be more detailed. More informational 
need on the "manual" changes introduced in the structures. 
Indeed, this was not explained adequately in the initial version of the manuscript. A detailed 
protocol was added to Section 2.7 of the Supporting Information. In brief: Schrodinger’s 
software Maestro includes a “Mutate Residue” function. Using this function, we individually 
mutated all non-conserved residues (these are only a few). This is a reproducible process 
without a random element. The conformations of the individual amino acids were then 
optimized during several steps of energy minimization and the initial 10 ns of molecular 
dynamics simulations, which were not used for analysis. 
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Molecular mechanism of a specific capsid inhibitor resistance caused by mutations 
outside the binding pocket 
 Single-site mutations were confirmed as cause of high-resistance (HR) to capsid-binding 
inhibitors of enteroviruses. 
 Two new HR amino acid substitutions were identified in position 1207 of viral capsid 
protein 1. 
 I1207K and I1207R are located outside the ligand binding site and do not affect viral 
replication. 
 Substitution of I1207 by a more bulky, positively charged residue pushes neighboring 
R1095 into the hydrophobic pocket, ultimately leading to the abolishment of drug action. 
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Abstract 
Enteroviruses cause various acute and chronic diseases. CapsidThe most promising 
therapeutics for these infections are capsid-binding inhibitors actingmolecules. These can act 
against a broad spectrum of enteroviruses represent most promising drug candidates for 
treatment of these infections today, but emerging drug-resistant virus variants threaten their 
therapeutic efficacy. All high-resistance known enterovirus variants characterized so far 
showwith high-level resistance toward capsid-binding molecules have mutations of residues 
directly involved in the formation of the hydrophobic drug binding pocket. Here wesite. This is 
a first report two new high-of substitutions outside the binding pocket causing this type of 
drug resistance conferring amino acid substitutions in position 1207 (: I1207K, and I1207R) 
of the viral capsid protein 1 of coxsackievirus B3. Both substitutions completely abolish the 
antiviral activity of pleconaril (a capsid-binding inhibitor) without affecting virusmolecule) but 
do not affect viral replication rates in vitro. Importantly, residue 1207 is not part of the drug 
binding pocket and hence not in direct interaction with pleconaril. Using molecularMolecular 
dynamics simulations a indicate that the resistance mechanism drivenis mediated by a 
conformational rearrangement of R1095 (, which is a neighboring residue of 1207) located at 
the heel of the drug binding pocket, was derived. These insights on the likely drug resistance 
mechanism might provide a basis for the design of novel resistance-breaking inhibitors. 
Formatted: Not Highlight
  
1 Introduction 
Echoviruses, coxsackie A and B viruses, enteroviruses, and rhinoviruses belong to the genus 
enterovirus (EV) of the family picornaviridae family (Rollinger and Schmidtke, 2011)(Rollinger 
and Schmidtke, 2011). They cause a wide range of acute and chronic diseases such as 
respiratory infections, meningitis, pancreatitis, encephalitis, and myocarditis (Pallansch and 
Roos, 2007; Turner and Couch, 2007).(Pallansch and Roos, 2007; Turner and Couch, 2007). 
As of today no therapeutics have been approved for the treatment of these infections (De 
Palma et al., 2008; Rollinger and Schmidtke, 2011)(De Palma et al., 2008; Rollinger and 
Schmidtke, 2011). Several capsid-binding inhibitorsmolecules (CIs) are being investigated as 
promising drug candidates (Andries et al., 1991; Diana, 2003; Makarov et al., 2005; Watson 
et al., 2003)(Andries et al., 1991; Diana, 2003; Makarov et al., 2005; Watson et al., 2003), 
the most developed ones being pleconaril and vapendavir (Diana et al., 1995; Feil et al., 
2012)(Diana et al., 1995; Feil et al., 2012). 
The architecture of the viral capsid is conserved among enteroviruses (Rossmann et al., 
2002), which provides the basis for the design of broad-spectrum CIs The architecture of the 
viral capsid is conserved among enteroviruses (Rossmann et al., 2002), which provides the 
basis for the design of broad-spectrum CIs (Ledford et al., 2005; Pevear et al., 1999; 
Schmidtke et al., 2005; Tijsma et al., 2014)(Ledford et al., 2005; Pevear et al., 1999; 
Schmidtke et al., 2005; Tijsma et al., 2014). The viral capsid consists of 60 promoters 
(Racaniello, 2007), each of them composed of four viral capsid proteins, VP1-4. In VP1, a 
hydrophobic pocket is present which in most EVs is occupied by a fatty acid. This pocket 
factor stabilizes the capsid and is released during the viral attachment, thereby facilitating 
viral uncoating (Rossmann et al., 2002). CIs are known to bind to this hydrophobic pocket 
and trigger conformational rearrangements in the viral capsid . The viral capsid consists of 60 
protein subunits (Racaniello, 2007), each of them composed of four viral capsid proteins, 
VP1-4. In VP1, a hydrophobic pocket is present which in most EVs is occupied by a fatty 
acid. This pocket factor stabilizes the capsid and is released during the viral attachment, 
thereby facilitating viral uncoating (Rossmann et al., 2002). CIs are known to bind to this 
  
hydrophobic pocket and trigger conformational rearrangements in the viral capsid (Grant et 
al., 1994; Kim et al., 1993; Muckelbauer et al., 1995a; Zhang et al., 2004)(Grant et al., 1994; 
Kim et al., 1993; Muckelbauer et al., 1995a; Zhang et al., 2004). Subsequently, attachment of 
viruses to host cells and/or uncoating is blocked (Diana et al., 1989; Pevear et al., 
1989)(Diana et al., 1989; Pevear et al., 1989). Study resultsStudies also suggest that drug 
integration during assembly additionally contributes to the antiviral activity of CIs (Zhang et 
al., 2004)(Zhang et al., 2004). 
Due to the high mutation raterates of RNA viruses (Domingo, 1989; Drake et al., 
1998)(Domingo, 1989; Drake et al., 1998) emerging drug resistance poses a threat to 
efficacy of CIs. All high-level resistance (HR) (Heinz et al., 1989)(Heinz et al., 1989) to CIs 
reported to date involve residues forming the hydrophobic pocket of EVEVs (Badger et al., 
1989; Benschop et al., 2015; Groarke and Pevear, 1999; Ledford et al., 2005; Ledford et al., 
2004; Schmidtke et al., 2005)(Badger et al., 1989; Benschop et al., 2015; Groarke and 
Pevear, 1999; Ledford et al., 2005; Ledford et al., 2004; Schmidtke et al., 2005), hence 
directly interfering with the binding of CIs. Because of similarities in the binding mode of CIs, 
cross-resistance may be observed, as reported for pleconaril and vapendavir (Feil et al., 
2012)(Feil et al., 2012). 
Here, mutations conferring HRhigh-level resistance were further investigated using a clinical 
coxsackievirus B3 (CVB3) in combination with pleconaril. For the first time substitutions of an 
amino acid outside the hydrophobic pocket targeted by CICIs were shown to cause HR.high-
level resistance. A hypothesis of the underlying molecular mechanism was derived byfrom 
molecular dynamics (MD) simulations. 
 
2 Materials and methods 
2.1 Synthesis and chemical analysis. 
All chemicals and solvents were purchased from Sigma‐Aldrich or Alfa Aesar. Pleconaril was 
synthesized from commercially available starting materials following a previously reported 
  
procedure (Diana et al., 1995)(Diana et al., 1995). The full protocol isprotocols are provided 
as Supplementary materialin the Supporting Information. 
 
2.2 Viruses and cells 
Virus stock of clinical CVB3 isolate 97927 (CVB3 97927; Robert Koch Institute, Berlin, 
Germany) was prepared in HeLa Ohio cells (HeLa cell; FlowLabs, USA) and sequenced 
previously (Schmidtke et al., 2005)(Schmidtke et al., 2005). 
HeLa cells were grown in Eagles minimal essential medium (Lonza Walkersville) 
supplemented with 10% fetal calf serum (PAA, Pasching, Austria), 100 U/ml penicillin, and 
100 U/ml streptomycin (Lonza, Walkersville). The test medium contained only 2% serum. 
 
2.3 Isolation of pleconaril-resistant CVB3 variants 
Nine independently prepared pools of wildtype CVB3 97927 (wt-CVB3 97927) were 
incubated with 1 µg/ml of pleconaril in test medium for 1 h at 37°C as described previously 
(Groarke and Pevear, 1999). An untreated virus pool served as control. Then, serial tenfold 
dilutions of all pools were added to confluent HeLa cell monolayers and overlaid with agar 
containing 1 µg/ml of pleconaril. After further 48 h of incubation at 37°C one plaque from 
each pool was picked. It was further two rounds plaque-to-plaque purified in the presence of 
1 µg/ml pleconaril and propagated in HeLa cells to get a(Groarke and Pevear, 1999). An 
untreated virus pool served as control. Then, serial tenfold dilutions of all pools were added 
to confluent HeLa cell monolayers and overlaid with agar containing 1 µg/ml of pleconaril. 
After further 48 h of incubation at 37°C one plaque from each pool was picked. It was further 
plaque-to-plaque purified for two rounds in the presence of 1 µg/ml pleconaril and 
propagated in HeLa cells to generate virus stocks. 
 
2. 4 Drug susceptibility testing 
Plaque reduction assays were performed (with approximately 30-40 plaque-forming units of 
wt-CVB3 97927 or its variants and up to 8.0 µg/ml of pleconaril) and cytopathic effect (CPE) 
  
inhibition assays were performed in HeLa cell monolayers as described previously 
(Schmidtke et al., 2001)(Schmidtke et al., 2001).  
Additionally, viral protein expression was analyzed in HeLa cells that were infected with wt-
CVB3 97927 and its variants (multiplicity of infection (moi) of 10 pfu/cell) in absence or 
presence of 1 µg/ml pleconaril for 5 hours. After fixation, CVB3 antigen was detected with a 
monoclonal antibody (mAK948, CHEMICON, USA) and the DAKO Real Detection System 
APAAP Mouse (DAKO, Glostrup, Denmark) as described previously (Zautner et al., 
2006)(Zautner et al., 2006) 
 
2.5 RNA isolation, RT-PCR, and sequencing of the capsid protein -encoding region P1  
RNA-isolation and RT-PCR of the P1 encoding region of CVB3 97927 variants was 
performed as described previously (Schmidtke et al., 2005)(Schmidtke et al., 2005) using 
primer pairs summarized in Table S1. PCR was carried out with the Taq Core Kit 10 (MP 
Biomedicals, formerly QBIOgeneQbiogene; France): 1 cycle of 93°C for 5 min; 35 cycles of 
94°C for 1 min, 55°C for 50 s and 72°C for 1 or 3 min, and a final cycle of 72°C for 20 min. 
Sequence analysis of the genome region P1 coding for capsid proteins (purified PCR 
products) was performed with the Beckman Coulter Genom-Lab System (PubMed GenBank 
number: JX946654 and JX946654) following the manufacturer’s instructions. Sequencing 
primers are summarized in Table S1. 
 
2.6 Comparison of single-step growth curves 
Single-step replication cycles of wt-CVB3 97927 and three selected pleconaril-resistant 
variants were comparatively studied in two-day-old confluent HeLa cells grown in 4-well 
tissue culture plates. Three wells of each plate were infected with a moi of 10 pfu/cell for 1 h 
at 37°C. After three washing steps, addition of fresh medium, and further incubation for 1 h, 2 
h, 3 h, 4 h, 6 h, 8 h, 10 h, and 12 h p.i., supernatant of each of the three infected wells was 
collected. Virus titers were determined in HeLa cells (Reed and Muench, 1938).(Reed and 
Muench, 1938). The Mann-Whitney-U-test was used for statistical analysis. 
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2.7 Computational studies 
Homology models for CVB3 97927 were manually derived from PDB structure 1COV 
(Muckelbauer et al., 1995b). Molecular dynamics simulations were carried out using the 
AMBER11 (with patches up to 17 applied) and the AMBERTOOLS version 1.5 suite of 
programs Homology models for the CVB3 97927 variants were derived using PDB 1cov 
(Muckelbauer et al., 1995b) as a template. Molecular dynamics simulations were carried out 
using AMBER11 and the AMBERTOOLS suite of programs (Case et al., 2010)(Case et al., 
2010). The full protocol isprotocols are provided asin the Supplementary materialInformation. 
 
3 Results 
3.1 Selection and characterization of pleconaril-resistant CVB3 variants 
The fraction of HRhigh-level resistant mutants present in a population of wt-CVB3 97927 was 
examined by determining the frequency of survivors that can replicate in presence of the 
drug (Heinz et al., 1989)(Heinz et al., 1989). Pleconaril . In analogy to earlier studies 
(Groarke and Pevear, 1999), pleconaril was applied at a high concentration of 1 µg/ml in 
analogy to earlier studies (Groarke and Pevear, 1999).. This concentration reduced the 
plaque titer of wt-CVB3 97927 by approximately four log units (Table 1). Based on these 
data, the frequency of pleconaril resistance in the wildtype population was 1.2 x 10-4.  
ToIn order to select HRhigh-level resistant mutants, nine pools of wt-CVB3 97927, treated 
individually with 1 µg/ml of pleconaril for 1 h at 37°C, were subjected to a plaque assay. Virus 
from one plaque per pool was collected and two tinespurified twice plaque-to-plaque purified 
in the presence of 1 µg/ml of pleconaril. For all nine purified isolates HRhigh-level resistance 
was demonstratedconfirmed in plaque reduction assays with 8 µg/ml of pleconaril (inactive) 
and in cytopathic effect inhibition assays for selected variants (one per mutation; Table 1.). 
These results were confirmed for three purified isolatescorroborated by 
immunohistochemical detection of viral antigen (Figure 2A) with pleconaril in HeLa cells. The 
wt-CVB3 97927 was included as a control and was found susceptible to pleconaril.  
  
No difference inClosely related antigen expression profiles of untreated HeLa cells infected 
with wt-CVB3 97927 and HRhigh-level resistant variants waswere observed (Figure 2A). The 
number of infected cells was even slightly higher for the I1092M variant than for the wt-
CVB3 97927. Furthermore, no significant difference was detected with the Mann-Whitney-U 
test, comparing single-step growth curves of wt-CVB3 97927 and HRhigh-level resistant 
variants in HeLa cells (Figure 2B). So; Table S2). Hence, replication of the selected HRhigh-
level resistant variants was not hampered in vitro. 
ToIn order to gain insight into the genetic basis of the detected pleconaril resistance, the 
whole capsid-protein-coding region P1 of all nine plaque-purified, HR high-level resistant 
variants was sequenced and compared with that of wt-CVB3 97927. All HRhigh-level 
resistant variants showed nucleotide exchanges that result in single-site amino acid 
substitution in position 1092 or 1207 (Table 1; Figure 1). I1092M substitution was detected 
for three HRhigh-level resistant variants. Six HRhigh-level resistant variants consisted 
singleshowed hitherto unknown amino acid substitutions at position 1207 (I1207K, I1207R), 
located outside the drug-binding pocket that were not described before.). 
 
3.2 Hypothesis of a specific drug resistance mechanism 
The A model of the resistance mechanism of HRCVB3 to pleconaril caused by I1207K and 
I1207R was investigateddeveloped using MD simulations of a homology model of wt-
CVB3 97927. Two copies of VP1-VP4 (one with pleconaril bound and one with the pocket 
factor bound) of the drug-sensitive and the two HR variantssimulation techniques. Six 
systems were simulated for 30 ns each. The : The wt-CVB3 97927 and the I1207K and 
I1207R variants, each in their apo and holo (i.e. bound with pleconaril) states. Each model 
was simulated for 30 ns; the last 20 ns were used for analysis. Structural 
All systems were stable for the full duration of the simulations. Commonly observed structural 
changes were observeddetected for solvent-exposed areas of the capsid protein, while the 
protein core and active sitecores remained close to their start geometries (Figure 3). 
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The apo protein structures proved to be particularly stable. No significant conformational 
changes in the region of the binding pocket could be observed. I1207 is part of the GH loop 
of VP1 in wt-CVB3 97927 (Figure 1, 4A). Both I1207K and I1207R leadSubstitution by Lys or 
Arg leads to the formation of a new salt bridge with E2131 (Figure 4B,C). R1207 approaches 
) and in the case of I1207R also to interactions with E1105 in addition (Figure 4C). Both 
substitutions appear to have a weak, stabilizing effect on the surrounding region (Figure 3C). 
The stability of the apo simulations is a strong indication that both mutations do not induce 
conformational rearrangements of the capsid pocket that could completely prevent ligands 
(such as pleconaril) to approach the binding site. The fact that the mutations of I1207 do not 
affect viral replication rates (indicating an intact function of the pocket factor) supports his 
model. 
In contrast to the apo structure simulations, significant conformational rearrangements were 
observed for holo structure simulations, for which reason we focused our analysis on these 
systems. 
All MD simulations are based on homology models derived from an X-ray structure of CVB3 
with a palmitate bound to the hydrophobic pocket, which . This pocket factor forms a salt 
bridge with R1095.  
In, which during the MD simulation of the wt-CVB3 97927-pleconaril complex, R1095 turns 
away from the hydrophobic methylisoxazole to form hydrogen bonds with E1105 and N1211 
(Figure 4A). Interaction with the latter leads to stabilization of the βH strand and a tightening 
of the hydrophobic pocket. In both HRhigh-level resistant variants, R1095 is pushed toward 
the hydrophobic pocket because of the additional bulk and charge added by the side chains. 
Consequently, the polar side chain of R1095 faces the non-polar methylisoxazole group of 
pleconaril (Figure 4B, C). This leads to destabilization of the protein-ligand interaction and 
causes the βH and βC strands to drift apart (Figure 5A). In further consequence, hydrogen 
bonds formed between R1095 and S1190/N1191 increasingly replace the βH strand-
stabilizing interactions of R1095 and N1211 (Figure 5B). 
  
The converse shift of both strands results in the dilation of the hydrophobic pocket. For the 
I1207K variant this translates into RMSDs of up to 1.4 Å for N1211 (Figure 6A). Movement of 
the βH strand is more pronounced in the I1207R variant, which after 20 ns of simulation time 
is mostly found in an open conformation (RMSDs up to 1.8 Å for N1211). As a result of this 
shift, surface contacts between N1211 (also N121 and M1213) and pleconaril (Figure 6B) are 
diminished. Water molecules fill gaps between the drug and the protein. 
Throughout most of the simulation of wt-CVB3 97927, the distance between the polar head 
of R1095 and the methyl group of pleconaril is about 6 Å or greater (mean 6.5 Å; min. 
distance 4.7 Å; Figure 6C). While for I1207K the mean distance is comparable to that of wt-
CVB3 97927 (6.7 Å), for parts of the trajectory the side chain gets much closer to pleconaril 
(min. distance 3.9 Å). For I1207R the mean and minimum distances are just 4.6 Å and 3.2 Å, 
respectively. 
The mean RMSD for pleconaril throughoutin the wt-CVB3 97927 simulation is 0.9 Å (Figure 
6D). For I1207K and I1207R these RMSDsvalues are 1.4 Å and 1.1 Å, respectively. The 
maximum RMSD observed for the I1207K variant (2.3 Å) is significantly higher than for the 
wt-CVB3 97927 (1.5 Å) and the I1207R variant (1.7 Å). RMSD peaks are a result of the 
displacement of the methylisoxazolylpropoxy group from the floor of the hydrophobic pocket 
toward the pore by the charged guanidino group of R1095 (Figure S1). 
In the wt-CVB3 97927, the torsion angle Φ (as indicated in the scheme of Figure 1) shows 
infrequent swaps between two conformations, with Φ around +75 or -120 degrees (Figure S 
2AS2A). In both conformations the methylisoxazole moiety remains in contact with the 
hydrophobic part of N1211. In both mutants however, pleconaril shows strong fluctuations for 
Φ as a result of a loss of surface contacts with N1211, caused by the shift of the βH strand 
(Figure S 2BS2B,C). 
A water molecule mediating interactions between the isoxazole nitrogen and the side chains 
of T1094 and R1095 is part of the protein-ligand interaction network in the sensitive virus 
(Figure 4A). Even though in the I1207K mutant pleconaril maintains coordination with a water 
molecule at this position, this variant does not form interactions with R1095. The torsional 
  
fluctuations of the methylisoxazole add to the instability of the water-mediated interactions 
(Figure S 3AS3A). Changes are more significant for the I1207R variant. There, interactions 
mediated by this water molecule are partially replaced by interactions with T1093 (Figure 
S3), which, together with the altered conformation of R1095, causescause the 
conformational shift seen for the βC strand. 
 
4 Discussion 
For the first time this work characterizes HRhigh-level resistance to a CICIs of EVs caused 
by I1207K and I1207R substitution. It also confirms single-site substitution of I1092M as a 
cause of HRhigh-level resistance (Groarke and Pevear, 1999; Schmidtke et al., 
2005)(Groarke and Pevear, 1999; Schmidtke et al., 2005). In contrast to I1092, I1207 is not 
part of the drugligand binding pocket and confers HRhigh-level resistance by an unreported 
molecular mechanism. 
The detected frequency of pleconaril resistance of 1.2 × 10-4 corresponds to previously 
published data for pleconaril-resistant CVB3 (Groarke and Pevear, 1999) and drug-resistant 
mutants of other ssRNA viruses (frequencies reported are between 10-3 and 10-5) The 
detected frequency of pleconaril resistance of 1.2 × 10-4 corresponds to previously published 
data for pleconaril-resistant CVB3 (Groarke and Pevear, 1999) and drug-resistant mutants of 
other ssRNA viruses (frequencies reported are between 10-3 and 10-5) (Heinz et al., 1989; 
Stech et al., 1999; Wang et al., 1998)(Heinz et al., 1989; Stech et al., 1999; Wang et al., 
1998). The high mutation rate (Drake et al., 1998; Holland et al., 1982)(Drake et al., 1998; 
Holland et al., 1982) and the existence of quasi species (Domingo, 1992) are caused by (i) 
integration of one mismatched base per 104-105 bases by RNA-dependent RNA polymerase 
of ssRNA viruses and (ii) lack of a proof-reading ability of these enzymes. 
The amino acid substitution I1092M was described earlier by Groarke et al. (Groarke and 
Pevear, 1999), who also detected a CVB3 variant containing two amino acid substitutions, 
I1092L as well as L1207V. However, the impact of the L1207V mutation on the resistant 
phenotype remained unclear. According to the definition of Heinz et al.  and the existence of 
  
quasi species (Domingo, 1992) are caused by (i) integration of one mismatched base per 
104-105 bases by RNA-dependent RNA polymerase of ssRNA viruses and (ii) lack of a proof-
reading ability of these enzymes. 
The amino acid substitution I1092M was described earlier by Groarke et al. (Groarke and 
Pevear, 1999), who also detected a CVB3 variant containing two amino acid substitutions, 
I1092L as well as L1207V. However, the impact of the L1207V mutation on the resistant 
phenotype remained unclear. According to the definition of Heinz et al. (Heinz et al., 
1989)(Heinz et al., 1989), substitutions in I1092 confer HRhigh-level resistance (Groarke and 
Pevear, 1999; Schmidtke et al., 2005)(Groarke and Pevear, 1999; Schmidtke et al., 2005). 
This can be explained by the fact that I1092 is one of the 17 amino acids forming the 
hydrophobic pocket of CVB3 (Muckelbauer et al., 1995a). I1092 is situated in the center of 
the pocket and interacts with one of the two methyl groups of pleconaril’s phenyl ring. 
Substitutions of amino acids in the center of the pocket that confer HR have also been 
reported for rhinoviruses . This can be explained by the fact that I1092 is one of the 17 amino 
acids forming the hydrophobic pocket of CVB3 (Muckelbauer et al., 1995a). I1092 is situated 
in the center of the pocket and interacts with one of the two methyl groups of pleconaril’s 
phenyl ring. Substitutions of amino acids in the center of the pocket that confer high-level 
resistance have also been reported for rhinoviruses (Badger et al., 1989; Heinz et al., 1989; 
Ledford et al., 2005; Ledford et al., 2004; Zhang et al., 2004)(Badger et al., 1989; Heinz et 
al., 1989; Ledford et al., 2005; Ledford et al., 2004; Zhang et al., 2004) and echovirus 11 
(Benschop et al., 2015)(Benschop et al., 2015). The activity of pleconaril derivatives lacking 
one or both of the methyl groups of the central phenyl ring of pleconaril (Schmidtke et al., 
2009)(Schmidtke et al., 2009) is less affected by the substitution of I1092.  
In contrast to I1092, I1207 is not involved in the formation of the drug-binding pocket 
(Muckelbauer et al., 1995a). Therefore, the observation that mutation of I1207 can lead to a 
complete loss of drug action is intriguing. MD simulations indicate that substitution of I1207 
by a more bulky, positively charged residue pushes R1095 into the hydrophobic pocket 
toward pleconaril, initiating a cascade of conformational changes, ultimately leading to the 
  
abolishment of drug action. Both the binding mode of pleconaril and the postulated drug 
resistance mechanism show similarities with oseltamivir resistance of influenza viruses 
caused by H274Y (Wang et al., 2002). The active site of influenza neuraminidase is highly 
polar In contrast to I1092, I1207 is not involved in the formation of the binding pocket 
(Muckelbauer et al., 1995a). Therefore, the observation that mutation of I1207 can lead to a 
complete loss of drug action is intriguing. MD simulations indicate that substitution of I1207 
by a more bulky, positively charged residue pushes R1095 into the hydrophobic pocket 
toward pleconaril, initiating a cascade of conformational changes that ultimately lead to the 
abolishment of drug action. Importantly, the substitutions appear to not lead to 
conformational rearrangements of the ligand binding site in the apo system, which otherwise 
could completely impair ligand binding. 
The postulated resistance mechanism has similarities with that of influenza virus 
neuraminidase and oseltamivir. Substitution of H274 by a Tyr leads to a substantial loss of 
affinity of oseltamivir for neuraminidase (Wang et al., 2002). The pentanyl substituent of 
oseltamivir forms hydrophobic interactions with the protein. In H274Y variants, the larger Tyr 
pushes the polar side chain of neighboring E276 farther into the binding site, toward the 
hydrophobic pentanyl moiety (von Grafenstein et al., 2015; von Itzstein, 2007)(Collins et al., 
2008). In search for orally effective neuraminidase inhibitors oseltamivir, comprising a 
pentanyl substituent was designed. This hydrophobic substituent causes the polar side chain 
of E276 to adopt its conformation and interact with R224. A hydrophobic pocket is created to 
which oseltamivir binds with high affinity (Kim et al., 1997). In the case of pleconaril it is the 
polar side chain of R1095 that points into the ligand binding pocket. In CVB3 97927, in 
presence of pleconaril the side chain of R1095 is reoriented to face away from the ligand and 
interact with the protein. In influenza neuraminidase, H274Y is located in the second shell of 
amino acids forming the active site. The larger tyrosine disrupts the interaction of E276 and 
R224, forcing E276 to point with its polar head group into the binding site, in direction of the 
hydrophobic substituent of oseltamivir (Russell et al., 2006). In the resistance mechanism 
postulated herein for CVB3 97927 and pleconaril it is R1095 which is pushed toward the 
  
hydrophobic ligand by the replacement of I1207 by a larger lysine or arginine. Methods and 
approaches described can be applied to study similar cases of resistance formation. 
A. This leads to high-level resistance against oseltamivir. In the case of the CVB3 97927 
I1207 mutants and pleconaril it is the polar side chain of R1095 that is pushed toward the 
hydrophobic ligand. 
An NCBI database survey with standard nucleotide blast demonstrated a polymorphism at 
position 1092 as well as 1207 in VP1 of CVB3. About 99% of the available CVB3 sequences 
express I1207, three have a V1207 and each one a T1207 or L1207. With respect to 
substitutions at position 1092, 30% of available sequences have isoleucine, 3% leucine and 
67% valine. Thus, viruses with substitutions in position 1092 or 1207 are circulating in nature. 
Obviously, they do not hamper viral replication. This is in good agreement with the results of 
our in vitro studies. Neither antigen expression nor one-step growth curves of CVB3 97927 
and HRhigh-level resistant mutants showed any differences. In contrast, attenuated virulence 
of pleconaril-resistant CVB3 with I1092L or I1092M was described in vivo (Groarke and 
Pevear, 1999)(Groarke and Pevear, 1999) but highly mouse-pathogenic, pleconaril-resistant 
CVB3 containing these substitutions also exist (Schmidtke et al., 2005; Schmidtke et al., 
2007)(Schmidtke et al., 2005; Schmidtke et al., 2007).  
The data presented here underline the vulnerability of the therapeutic efficacy of antivirals 
targeting the hydrophobic pocket of picornaviruses. The identificationKnowledge of 1207 as 
further the key role of residue for CIs1207 in CI activity and the understanding of the 
underlying drug-new model of a specific resistance mechanism are valuable for the rational 
design of future therapeutic agents with superior resistance profiles. 
 
5 References 
6 Andries, K., Dewindt, B., Snoeks, J., Willebrords, R., Stokbroekx, R., Lewi, P.J., 1991. 
A comparative test of fifteen compounds against all known human rhinovirus serotypes as a 
basis for a more rational screening program. Antiviral research 16, 213-225. 
7 Badger, J., Krishnaswamy, S., Kremer, M.J., Oliveira, M.A., Rossmann, M.G., Heinz, 
B.A., Rueckert, R.R., Dutko, F.J., McKinlay, M.A., 1989. Three-dimensional structures of 
drug-resistant mutants of human rhinovirus 14. Journal of molecular biology 207, 163-174. 
8 Benschop, K.S., Wildenbeest, J.G., Koen, G., Minnaar, R.P., van Hemert, F.J., 
Westerhuis, B.M., Pajkrt, D., van den Broek, P.J., Vossen, A.C., Wolthers, K.C., 2015. 
Formatted: EndNote Bibliography
Field Code Changed
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
  
Genetic and antigenic structural characterization for resistance of echovirus 11 to pleconaril 
in an immunocompromised patient. The Journal of general virology 96, 571-579. 
9 Case   . .   arden   . .  Cheatham   . .  Simmerling  C.L.   ang  J.   uke   . .  
Luo   .  alker   .C.   hang  .  Merz  K.M.   oberts   .  ang   .  Hayik  S.   oitberg   .  
Seabra   .  Kolossv ry, I., Wong, K.F., Paesani, F., Vanicek, J., Liu, J., Wu, X., Brozell, S.R., 
Steinbrecher, T., Gohlke, H., Cai, Q., Ye, X., Wang, J., Hsieh, M.-J., Cui, G., Roe, D.R., 
Mathews, D.H., Seetin, M.G., Sagui, C., Babin, V., Luchko, T., Gusarov, S., Kovalenko, A., 
Kollman, P.A., 2010. AMBER 11. University of California, San Francisco. 
Collins, P.J., Haire, L.F., Lin, Y.P., Liu, J., Russell, R.J., Walker, P.A., Skehel, J.J., Martin, 
S.R., Hay, A.J., Gamblin, S.J., 2008. Crystal structures of oseltamivir-resistant influenza virus 
neuraminidase mutants. Nature 453, 1258-1261. 
10 De Palma, A.M., Vliegen, I., De Clercq, E., Neyts, J., 2008. Selective inhibitors of 
picornavirus replication. Medicinal research reviews 28, 823-884. 
11 Diana, G.D., 2003. Inhibitors of picornavirus replication. Current medicinal chemistry 
2, 1-12. 
12 Diana, G.D., Pevear, D.C., Otto, M.J., McKinlay, M.A., Rossmann, M.G., Smith, T., 
Badger, J., 1989. Inhibitors of viral uncoating. Pharmacology & therapeutics 42, 289-305. 
13 Diana, G.D., Rudewicz, P., Pevear, D.C., Nitz, T.J., Aldous, S.C., Aldous, D.J., 
Robinson, D.T., Draper, T., Dutko, F.J., Aldi, C., et al., 1995. Picornavirus inhibitors: 
trifluoromethyl substitution provides a global protective effect against hepatic metabolism. 
Journal of medicinal chemistry 38, 1355-1371. 
14 Domingo, E., 1989. RNA virus evolution and the control of viral disease. Progress in 
drug research. Fortschritte der Arzneimittelforschung 33, 93-133. 
15 Domingo, E., 1992. Genetic variation and quasi-species. Curr Opin Genet Dev 2, 61-
63. 
16 Drake, J.W., Charlesworth, B., Charlesworth, D., Crow, J.F., 1998. Rates of 
spontaneous mutation. Genetics 148, 1667-1686. 
17 Feil, S.C., Hamilton, S., Krippner, G.Y., Lin, B., Luttick, A., McConnell, D.B., Nearn, 
R., Parker, M.W., Ryan, J., Stanislawski, P.C., Tucker, S.P., Watson, K.G., Morton, C.J., 
2012. An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against 
Human Rhinovirus. ACS medicinal chemistry letters 3, 303-307. 
18 Grant, R.A., Hiremath, C.N., Filman, D.J., Syed, R., Andries, K., Hogle, J.M., 1994. 
Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and 
drug design. Current biology : CB 4, 784-797. 
19 Groarke, J.M., Pevear, D.C., 1999. Attenuated virulence of pleconaril-resistant 
coxsackievirus B3 variants. The Journal of infectious diseases 179, 1538-1541. 
20 Heinz, B.A., Rueckert, R.R., Shepard, D.A., Dutko, F.J., McKinlay, M.A., Fancher, M., 
Rossmann, M.G., Badger, J., Smith, T.J., 1989. Genetic and molecular analyses of 
spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. 
Journal of virology 63, 2476-2485. 
21 Holland, J., Spindler, K., Horodyski, F., Grabau, E., Nichol, S., VandePol, S., 1982. 
Rapid evolution of RNA genomes. Science 215, 1577-1585. 
22 Kim, C.U., Lew, W., Williams, M.A., Liu, H., Zhang, L., Swaminathan, S., Bischofberger, 
N., Chen, M.S., Mendel, D.B., Tai, C.Y., Laver, W.G., Stevens, R.C., 1997. Influenza 
neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active 
site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent 
anti-influenza activity. Journal of the American Chemical Society 119, 681-690. 
23 Kim, K.H., Willingmann, P., Gong, Z.X., Kremer, M.J., Chapman, M.S., Minor, I., 
Oliveira, M.A., Rossmann, M.G., Andries, K., Diana, G.D., et al., 1993. A comparison of the 
anti-rhinoviral drug binding pocket in HRV14 and HRV1A. Journal of molecular biology 230, 
206-227. 
24 Ledford, R.M., Collett, M.S., Pevear, D.C., 2005. Insights into the genetic basis for 
natural phenotypic resistance of human rhinoviruses to pleconaril. Antiviral research 68, 135-
138. 
25 Ledford, R.M., Patel, N.R., Demenczuk, T.M., Watanyar, A., Herbertz, T., Collett, 
M.S., Pevear, D.C., 2004. VP1 sequencing of all human rhinovirus serotypes: insights into 
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: EndNote Bibliography
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: EndNote Bibliography
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
  
genus phylogeny and susceptibility to antiviral capsid-binding compounds. Journal of virology 
78, 3663-3674. 
26 Makarov, V.A., Riabova, O.B., Granik, V.G., Wutzler, P., Schmidtke, M., 2005. Novel 
[(biphenyloxy)propyl]isoxazole derivatives for inhibition of human rhinovirus 2 and 
coxsackievirus B3 replication. The Journal of antimicrobial chemotherapy 55, 483-488. 
27 Muckelbauer, J.K., Kremer, M., Minor, I., Diana, G., Dutko, F.J., Groarke, J., Pevear, 
D.C., Rossmann, M.G., 1995a. The structure of coxsackievirus B3 at 3.5 A resolution. 
Structure 3, 653-667. 
28 Muckelbauer, J.K., Kremer, M., Minor, I., Tong, L., Zlotnick, A., Johnson, J.E., 
Rossmann, M.G., 1995b. Structure determination of coxsackievirus B3 to 3.5 A resolution. 
Acta crystallographica. Section D, Biological crystallography 51, 871-887. 
29 Pallansch, M., Roos, R., 2007. Enteroviruses: plioviruses, coxsackieviruses, 
echoviruses, and newer enteroviruses, in: Knipe, D., Howley, P. (Eds.), Fields Virology. 
Lippincott Williams Wilkins, Philadelphia, pp. 839-894. 
30 Pevear, D.C., Fancher, M.J., Felock, P.J., Rossmann, M.G., Miller, M.S., Diana, G., 
Treasurywala, A.M., McKinlay, M.A., Dutko, F.J., 1989. Conformational change in the floor of 
the human rhinovirus canyon blocks adsorption to HeLa cell receptors. Journal of virology 
63, 2002-2007. 
31 Pevear, D.C., Tull, T.M., Seipel, M.E., Groarke, J.M., 1999. Activity of pleconaril 
against enteroviruses. Antimicrobial agents and chemotherapy 43, 2109-2115. 
32 Racaniello, V., 2007. Picornaviridae: The viruses and their replication, in: Knipe, D., 
Howley, P. (Eds.), Fields Virology. Lippinscott Williams & Wilkins, a Wolters Kluwer 
Business, Philadelphia, pp. 795-838. 
33 Reed, L., Muench, H., 1938. A simple method of estimating fifty per cent endpoints. 
American Journal Hygiene 27, 493. 
34 Rollinger, J.M., Schmidtke, M., The human rhinovirus: human-pathological impact, 
mechanisms of antirhinoviral agents, and strategies for their discovery. Med Res Rev 31, 42-
92. 
35 Rollinger, J.M., Schmidtke, M., 2011. The human rhinovirus: human-pathological 
impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Medicinal 
research reviews 31, 42-92. 
36 Rossmann, M.G., He, Y., Kuhn, R.J., 2002. Picornavirus-receptor interactions. Trends 
in microbiology 10, 324-331. 
37 Russell, R.J., Haire, L.F., Stevens, D.J., Collins, P.J., Lin, Y.P., Blackburn, G.M., Hay, 
A.J., Gamblin, S.J., Skehel, J.J., 2006. The structure of H5N1 avian influenza neuraminidase 
suggests new opportunities for drug design. Nature 443, 45-49. 
38 Schmidtke, M., Hammerschmidt, E., Schuler, S., Zell, R., Birch-Hirschfeld, E., 
Makarov, V.A., Riabova, O.B., Wutzler, P., 2005. Susceptibility of coxsackievirus B3 
laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral 
studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. The 
Journal of antimicrobial chemotherapy 56, 648-656. 
39 Schmidtke, M., Merkle, I., Klingel, K., Hammerschmidt, E., Zautner, A.E., Wutzler, P., 
2007. The viral genetic background determines the outcome of coxsackievirus B3 infection in 
outbred NMRI mice. Journal of medical virology 79, 1334-1342. 
40 Schmidtke, M., Schnittler, U., Jahn, B., Dahse, H., Stelzner, A., 2001. A rapid assay 
for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes 
simplex virus type 1. Journal of virological methods 95, 133-143. 
41 Schmidtke, M., Wutzler, P., Zieger, R., Riabova, O.B., Makarov, V.A., 2009. New 
pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring 
exhibit antiviral activity against pleconaril-resistant coxsackievirus B3. Antiviral research 81, 
56-63. 
42 Stech, J., Xiong, X., Scholtissek, C., Webster, R.G., 1999. Independence of 
evolutionary and mutational rates after transmission of avian influenza viruses to swine. 
Journal of virology 73, 1878-1884. 
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: EndNote Bibliography
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
(U.S.)
Formatted: Font: 11 pt
Formatted: Font: 11 pt, English
Formatted: Font: 11 pt
  
43 Tijsma, A., Franco, D., Tucker, S., Hilgenfeld, R., Froeyen, M., Leyssen, P., Neyts, J., 
2014. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit 
enterovirus 71 replication. Antimicrobial agents and chemotherapy 58, 6990-6992. 
44 Turner, R.B., Couch, R.B., 2007. Rhinoviruses, in: Knipe, D.M., Howley, P.M. (Eds.), 
Fields Virology. Lippencott Williams & Wilkins, Philadelphia, PA, USA, pp. 895-909. 
45 von Grafenstein, S., Wallnoefer, H.G., Kirchmair, J., Fuchs, J.E., Huber, R.G., Schmidtke, 
M., Sauerbrei, A., Rollinger, J.M., Liedl, K.R., 2015. Interface dynamics explain assembly 
dependency of influenza neuraminidase catalytic activity. J Biomol Struct Dyn 33, 104-120. 
46 von Itzstein, M., 2007. The war against influenza: discovery and development of 
sialidase inhibitors. Nat Rev Drug Discov 6, 967-974. 
47 Wang, M.Z., Tai, C.Y., Mendel, D.B., 2002. Mechanism by which mutations at his274 
alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and 
zanamivir. Antimicrobial agents and chemotherapy 46, 3809-3816. 
48 Wang, W., Lee, W.M., Mosser, A.G., Rueckert, R.R., 1998. WIN 52035-dependent 
human rhinovirus 16: assembly deficiency caused by mutations near the canyon surface. 
Journal of virology 72, 1210-1218. 
49 Watson, K.G., Brown, R.N., Cameron, R., Chalmers, D.K., Hamilton, S., Jin, B., 
Krippner, G.Y., Luttick, A., McConnell, D.B., Reece, P.A., Ryan, J., Stanislawski, P.C., 
Tucker, S.P., Wu, W.Y., Barnard, D.L., Sidwell, R.W., 2003. An orally bioavailable oxime 
ether capsid binder with potent activity against human rhinovirus. Journal of medicinal 
chemistry 46, 3181-3184. 
50 Zautner, A.E., Jahn, B., Hammerschmidt, E., Wutzler, P., Schmidtke, M., 2006. N- 
and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD 
into CHO-K1 cells. Journal of virology 80, 6629-6636. 
51 Zhang, Y., Simpson, A.A., Ledford, R.M., Bator, C.M., Chakravarty, S., Skochko, 
G.A., Demenczuk, T.M., Watanyar, A., Pevear, D.C., Rossmann, M.G., 2004. Structural and 
virological studies of the stages of virus replication that are affected by antirhinovirus 
compounds. Journal of virology 78, 11061-11069. 
52  
  
Figure captions 
Figure 1. Overview of the two protomers of the CVB3 97927 virus capsid as used for the MD 
simulations. VP1 (purple), VP2 (blue), VP3 (orange), VP4 (cyan). The GH loop and pleconaril are 
indicated in green and the second protomer in grey. The enlarged section shows VP1 with the location 
of pleconaril, I1092 and I1207. 
 
Figure 2. Replication of wt-CVB3 97927 and three different pleconaril-resistant variants in HeLa 
cells. HeLa cells were infected at a moi of 10 pfu/cell of the respective virus. (A) The influence of 
pleconaril treatment (1 µg/ml) on viral antigen expression was comparatively studied by 
immunohistochemical staining of CVB3-infected HeLa cells 5 h p.i. Virus antigen-positive cells are 
stained in red color. (B) Comparison of single-step life cycles of the selected CVB3 samples. Values 
represent the means and SD of 3 parallel measurements per time point. 
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Figure 3. Backbone RMSD. Development of the backbone RMSD of the (A) whole 
simulatedcomplete apo system and, (B) complete holo system, (C) pocket-forming residues. of the 
apo system and (D) pocket-forming residues of the holo system. wt-CVB3 97927 (black), I1207K 
(orange), I1207R (blue). 
 
Figure 4. Conformational flexibility of VP1 and molecular interactions of VP1 with pleconaril. 
(A) In the wt-CVB3 97927, R1095 forms polar interactions with E1105, N1211 and a water molecule. 
The polar side chain of R1095 is hence oriented away from pleconaril toward E1105. (B) In the I1207K 
mutant, K1207 forms a salt bridge with E2131 rather than E1105. R1095 points toward the 
hydrophobic ligand. (C) An initially observed salt bridge between R1207 and E1105 in the I1207R 
mutant is weakened by a conformational rearrangement of the βH strand observed during the 
simulation. In this resistant variant the charged side chain of R1095 points deeply into the hydrophobic 
pocket. (D) B-factors calculated for VP1 from the MD trajectories. wt-CVB3 97927 (black), I1207K 
(orange), I1207R (blue). The exposed residues of the GH loop show increased flexibility when 
compared to the mutants (in particular A1200). B-factor plots for VP2, 3 and 4 are provided in Figure 
S4. 
 
Figure 5. Conformational shifts observed for the βC and βH strands of the wt-CVB3 97927 and 
the two mutants. (A) Representative frame of the wt-CVB3 97927 (grey), I1207K (orange) and 
I1207  (blue) virus strain  selected from the M  trajectories by clustering. ( )  etail of the βH strand 
of the I1207R variant, before (green) and after (blue) the conformational shift. 
 
Figure 6. Conformational shift of the βH-strand induced by the approach of R1095, repelling the 
hydrophobic elements of pleconaril and N1211. (A) RMSD plot of N1211. (B) Distance between the 
aliphatic carbon of the methylisoxazole moiety of pleconaril and the Cα atom of N1211. (C) Distance 
between the guanidino carbon atom of R1095 and the aliphatic carbon of the methylisoxazole group. 
(D) RMSD plot of pleconaril. wt-CVB3 97927 (black), I1207K (orange) and I1207R (blue). 
 
  
 
Supporting Information 
 
Table S 1. Primers used for PCR amplification and sequencing. 
 
Table S2. Virus titers determined in one-step replication cycle experiments at different 
hours after infection with CVB3 97-927 variants. 
 
Figure S 1. ConformationConformations observed for pleconaril. Representative conformations 
selected from the wt-CVB3 97927 (grey), I1207K (orange) and I1207R (blue) trajectories using an 
average-linkage algorithm for clustering (considering only the conformations of the drug molecule).. 
 
Figure S 2. Conformational fluctuations of torsion angle Φ of pleconaril. (A) Fluctuations 
between two torsion angle states occur infrequently in the wt-CVB3 97927. They are much stronger for 
the (B) I1207K and (C) I1207R mutants. 
 
Figure S 3. InteractionInteractions of the isoxazole nitrogen of pleconaril with (A) water and (B) 
T1093. Even though an interaction of pleconaril with a water molecule is maintained in the mutants, 
the formed interaction network formed is much weaker when compared to thethan that of wt-CVB3 
97927 (black). In the I1207R mutant (blue) pleconaril is partially switching from an interaction with 
water to an interaction with T1093. 
 
Figure S 4. B-factors calculated for (a) VP2, (b) VP3 and (c) VP4. wt-CVB3 97927 (black), I1207K 
(orange), I1207R (blue). 
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Abstract 
Enteroviruses cause various acute and chronic diseases. The most promising therapeutics 
for these infections are capsid-binding molecules. These can act against a broad spectrum of 
enteroviruses, but emerging resistant virus variants threaten their efficacy. All known 
enterovirus variants with high-level resistance toward capsid-binding molecules have 
mutations of residues directly involved in the formation of the hydrophobic binding site. This 
is a first report of substitutions outside the binding pocket causing this type of drug 
resistance: I1207K and I1207R of the viral capsid protein 1 of coxsackievirus B3. Both 
substitutions completely abolish the antiviral activity of pleconaril (a capsid-binding molecule) 
but do not affect viral replication rates in vitro. Molecular dynamics simulations indicate that 
the resistance mechanism is mediated by a conformational rearrangement of R1095, which 
is a neighboring residue of 1207 located at the heel of the binding pocket. These insights 
provide a basis for the design of resistance-breaking inhibitors. 
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1 Introduction 
Echoviruses, coxsackie A and B viruses, enteroviruses and rhinoviruses belong to the genus 
enterovirus (EV) of the picornaviridae family (Rollinger and Schmidtke, 2011). They cause a 
wide range of acute and chronic diseases such as respiratory infections, meningitis, 
pancreatitis, encephalitis, and myocarditis (Pallansch and Roos, 2007; Turner and Couch, 
2007). As of today no therapeutics have been approved for the treatment of these infections 
(De Palma et al., 2008; Rollinger and Schmidtke, 2011). Several capsid-binding molecules 
(CIs) are being investigated as promising drug candidates (Andries et al., 1991; Diana, 2003; 
Makarov et al., 2005; Watson et al., 2003), the most developed ones being pleconaril and 
vapendavir (Diana et al., 1995; Feil et al., 2012). 
The architecture of the viral capsid is conserved among enteroviruses (Rossmann et al., 
2002), which provides the basis for the design of broad-spectrum CIs (Ledford et al., 2005; 
Pevear et al., 1999; Schmidtke et al., 2005; Tijsma et al., 2014). The viral capsid consists of 
60 protein subunits (Racaniello, 2007), each of them composed of four viral capsid proteins, 
VP1-4. In VP1, a hydrophobic pocket is present which in most EVs is occupied by a fatty 
acid. This pocket factor stabilizes the capsid and is released during the viral attachment, 
thereby facilitating viral uncoating (Rossmann et al., 2002). CIs are known to bind to this 
hydrophobic pocket and trigger conformational rearrangements in the viral capsid (Grant et 
al., 1994; Kim et al., 1993; Muckelbauer et al., 1995a; Zhang et al., 2004). Subsequently, 
attachment of viruses to host cells and/or uncoating is blocked (Diana et al., 1989; Pevear et 
al., 1989). Studies also suggest that drug integration during assembly additionally contributes 
to the antiviral activity of CIs (Zhang et al., 2004). 
Due to the high mutation rates of RNA viruses (Domingo, 1989; Drake et al., 1998) emerging 
drug resistance poses a threat to efficacy of CIs. All high-level resistance (Heinz et al., 1989) 
to CIs reported to date involve residues forming the hydrophobic pocket of EVs (Badger et 
al., 1989; Benschop et al., 2015; Groarke and Pevear, 1999; Ledford et al., 2005; Ledford et 
al., 2004; Schmidtke et al., 2005), hence directly interfering with the binding of CIs. Because 
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of similarities in the binding mode of CIs, cross-resistance may be observed, as reported for 
pleconaril and vapendavir (Feil et al., 2012). 
Here, mutations conferring high-level resistance were further investigated using a clinical 
coxsackievirus B3 (CVB3) in combination with pleconaril. For the first time substitutions of an 
amino acid outside the hydrophobic pocket targeted by CIs were shown to cause high-level 
resistance. A hypothesis of the underlying molecular mechanism was derived from molecular 
dynamics (MD) simulations. 
 
2 Materials and methods 
2.1 Synthesis and chemical analysis. 
All chemicals and solvents were purchased from Sigma‐Aldrich or Alfa Aesar. Pleconaril was 
synthesized from commercially available starting materials following a previously reported 
procedure (Diana et al., 1995). The full protocols are provided in the Supporting Information. 
 
2.2 Viruses and cells 
Virus stock of clinical CVB3 isolate 97927 (CVB3 97927; Robert Koch Institute, Berlin, 
Germany) was prepared in HeLa Ohio cells (HeLa cell; FlowLabs, USA) and sequenced 
previously (Schmidtke et al., 2005). 
HeLa cells were grown in Eagles minimal essential medium (Lonza Walkersville) 
supplemented with 10% fetal calf serum (PAA, Pasching, Austria), 100 U/ml penicillin, and 
100 U/ml streptomycin (Lonza, Walkersville). The test medium contained only 2% serum. 
 
2.3 Isolation of pleconaril-resistant CVB3 variants 
Nine independently prepared pools of wildtype CVB3 97927 (wt-CVB3 97927) were 
incubated with 1 µg/ml of pleconaril in test medium for 1 h at 37°C as described previously 
(Groarke and Pevear, 1999). An untreated virus pool served as control. Then, serial tenfold 
dilutions of all pools were added to confluent HeLa cell monolayers and overlaid with agar 
containing 1 µg/ml of pleconaril. After further 48 h of incubation at 37°C one plaque from 
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each pool was picked. It was further plaque-to-plaque purified for two rounds in the presence 
of 1 µg/ml pleconaril and propagated in HeLa cells to generate virus stocks. 
 
2. 4 Drug susceptibility testing 
Plaque reduction assays (with approximately 30-40 plaque-forming units of wt-CVB3 97927 
or its variants and up to 8.0 µg/ml of pleconaril) and cytopathic effect (CPE) inhibition assays 
were performed in HeLa cell monolayers as described previously (Schmidtke et al., 2001).  
Additionally, viral protein expression was analyzed in HeLa cells that were infected with wt-
CVB3 97927 and its variants (multiplicity of infection (moi) of 10 pfu/cell) in absence or 
presence of 1 µg/ml pleconaril for 5 hours. After fixation, CVB3 antigen was detected with a 
monoclonal antibody (mAK948, CHEMICON, USA) and the DAKO Real Detection System 
APAAP Mouse (DAKO, Glostrup, Denmark) as described previously (Zautner et al., 2006) 
 
2.5 RNA isolation, RT-PCR, and sequencing of the capsid protein-encoding region P1 
RNA-isolation and RT-PCR of the P1 encoding region of CVB3 97927 variants was 
performed as described previously (Schmidtke et al., 2005) using primer pairs summarized in 
Table S1. PCR was carried out with the Taq Core Kit 10 (MP Biomedicals, formerly 
Qbiogene; France): 1 cycle of 93°C for 5 min; 35 cycles of 94°C for 1 min, 55°C for 50 s and 
72°C for 1 or 3 min, and a final cycle of 72°C for 20 min. 
Sequence analysis of the genome region P1 coding for capsid proteins (purified PCR 
products) was performed with the Beckman Coulter Genom-Lab System (PubMed GenBank 
number: JX946654 and JX946654) following the manufacturer’s instructions. Sequencing 
primers are summarized in Table S1. 
 
2.6 Comparison of single-step growth curves 
Single-step replication cycles of wt-CVB3 97927 and three selected pleconaril-resistant 
variants were comparatively studied in two-day-old confluent HeLa cells grown in 4-well 
tissue culture plates. Three wells of each plate were infected with a moi of 10 pfu/cell for 1 h 
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at 37°C. After three washing steps, addition of fresh medium, and further incubation for 1 h, 2 
h, 3 h, 4 h, 6 h, 8 h, 10 h, and 12 h p.i., supernatant of each of the three infected wells was 
collected. Virus titers were determined in HeLa cells (Reed and Muench, 1938). The Mann-
Whitney-U-test was used for statistical analysis. 
 
2.7 Computational studies 
Homology models for the CVB3 97927 variants were derived using PDB 1cov (Muckelbauer 
et al., 1995b) as a template. Molecular dynamics simulations were carried out using 
AMBER11 and the AMBERTOOLS suite of programs (Case et al., 2010). The full protocols 
are provided in the Supplementary Information. 
 
3 Results 
3.1 Selection and characterization of pleconaril-resistant CVB3 variants 
The fraction of high-level resistant mutants present in a population of wt-CVB3 97927 was 
examined by determining the frequency of survivors that can replicate in presence of the 
drug (Heinz et al., 1989). In analogy to earlier studies (Groarke and Pevear, 1999), pleconaril 
was applied at a high concentration of 1 µg/ml. This concentration reduced the plaque titer of 
wt-CVB3 97927 by approximately four log units (Table 1). Based on these data the frequency 
of pleconaril resistance in the wildtype population was 1.2 x 10-4.  
In order to select high-level resistant mutants, nine pools of wt-CVB3 97927, treated 
individually with 1 µg/ml of pleconaril for 1 h at 37°C, were subjected to a plaque assay. Virus 
from one plaque per pool was collected and purified twice plaque-to-plaque in the presence 
of 1 µg/ml of pleconaril. For all nine purified isolates high-level resistance was confirmed in 
plaque reduction assays with 8 µg/ml of pleconaril (inactive) and in cytopathic effect inhibition 
assays for selected variants (one per mutation; Table 1). These results were corroborated by 
immunohistochemical detection of viral antigen (Figure 2A) with pleconaril in HeLa cells. wt-
CVB3 97927 was included as a control and was found susceptible to pleconaril.  
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Closely related antigen expression profiles of untreated HeLa cells infected with wt-
CVB3 97927 and high-level resistant variants were observed (Figure 2A). The number of 
infected cells was even slightly higher for the I1092M variant than for the wt-CVB3 97927. 
Furthermore, no significant difference was detected with the Mann-Whitney-U test, 
comparing single-step growth curves of wt-CVB3 97927 and high-level resistant variants in 
HeLa cells (Figure 2B; Table S2). Hence, replication of the selected high-level resistant 
variants was not hampered in vitro. 
In order to gain insight into the genetic basis of the detected pleconaril resistance, the whole 
capsid-protein-coding region P1 of all nine plaque-purified high-level resistant variants was 
sequenced and compared with that of wt-CVB3 97927. All high-level resistant variants 
showed nucleotide exchanges that result in single-site amino acid substitution in position 
1092 or 1207 (Table 1; Figure 1). I1092M substitution was detected for three high-level 
resistant variants. Six high-level resistant variants showed hitherto unknown amino acid 
substitutions at position 1207 (I1207K, I1207R). 
 
3.2 Hypothesis of a specific drug resistance mechanism 
A model of the resistance mechanism of CVB3 to pleconaril was developed using MD 
simulation techniques. Six systems were simulated: The wt-CVB3 97927 and the I1207K and 
I1207R variants, each in their apo and holo (i.e. bound with pleconaril) states. Each model 
was simulated for 30 ns; the last 20 ns were used for analysis. 
All systems were stable for the full duration of the simulations. Commonly observed structural 
changes were detected for solvent-exposed areas of the capsid protein, while the protein 
cores remained close to their start geometries (Figure 3). 
The apo protein structures proved to be particularly stable. No significant conformational 
changes in the region of the binding pocket could be observed. I1207 is part of the GH loop 
of VP1 (Figure 1, 4A). Substitution by Lys or Arg leads to the formation of a new salt bridge 
with E2131 (Figure 4B,C) and in the case of I1207R also to interactions with E1105 (Figure 
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4C). Both substitutions appear to have a weak, stabilizing effect on the surrounding region 
(Figure 3C). 
The stability of the apo simulations is a strong indication that both mutations do not induce 
conformational rearrangements of the capsid pocket that could completely prevent ligands 
(such as pleconaril) to approach the binding site. The fact that the mutations of I1207 do not 
affect viral replication rates (indicating an intact function of the pocket factor) supports his 
model. 
In contrast to the apo structure simulations, significant conformational rearrangements were 
observed for holo structure simulations, for which reason we focused our analysis on these 
systems. 
All MD simulations are based on homology models derived from an X-ray structure of CVB3 
with a palmitate bound to the hydrophobic pocket. This pocket factor forms a salt bridge with 
R1095, which during the MD simulation of the wt-CVB3 97927-pleconaril complex turns away 
from the hydrophobic methylisoxazole to form hydrogen bonds with E1105 and N1211 
(Figure 4A). Interaction with the latter leads to stabilization of the βH strand and a tightening 
of the hydrophobic pocket. In both high-level resistant variants, R1095 is pushed toward the 
hydrophobic pocket because of the additional bulk and charge added by the side chains. 
Consequently, the polar side chain of R1095 faces the non-polar methylisoxazole group of 
pleconaril (Figure 4B, C). This leads to destabilization of the protein-ligand interaction and 
causes the βH and βC strands to drift apart (Figure 5A). In further consequence, hydrogen 
bonds formed between R1095 and S1190/N1191 increasingly replace the βH strand-
stabilizing interactions of R1095 and N1211 (Figure 5B). 
The converse shift of both strands results in the dilation of the hydrophobic pocket. For the 
I1207K variant this translates into RMSDs of up to 1.4 Å for N1211 (Figure 6A). Movement of 
the βH strand is more pronounced in the I1207R variant, which after 20 ns of simulation time 
is mostly found in an open conformation (RMSDs up to 1.8 Å for N1211). As a result of this 
shift, surface contacts between N1211 (also N121 and M1213) and pleconaril (Figure 6B) are 
diminished. Water molecules fill gaps between the drug and the protein. 
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Throughout most of the simulation of wt-CVB3 97927, the distance between the polar head 
of R1095 and the methyl group of pleconaril is about 6 Å or greater (mean 6.5 Å; min. 
distance 4.7 Å; Figure 6C). While for I1207K the mean distance is comparable to that of wt-
CVB3 97927 (6.7 Å), for parts of the trajectory the side chain gets much closer to pleconaril 
(min. distance 3.9 Å). For I1207R the mean and minimum distances are just 4.6 Å and 3.2 Å, 
respectively. 
The mean RMSD for pleconaril in the wt-CVB3 97927 simulation is 0.9 Å (Figure 6D). For 
I1207K and I1207R these values are 1.4 Å and 1.1 Å, respectively. The maximum RMSD 
observed for the I1207K variant (2.3 Å) is significantly higher than for the wt-CVB3 97927 
(1.5 Å) and the I1207R variant (1.7 Å). RMSD peaks are a result of the displacement of the 
methylisoxazolylpropoxy group from the floor of the hydrophobic pocket toward the pore by 
the charged guanidino group of R1095 (Figure S1). 
In the wt-CVB3 97927, the torsion angle Φ (as indicated in the scheme of Figure 1) shows 
infrequent swaps between two conformations, with Φ around +75 or -120 degrees (Figure 
S2A). In both conformations the methylisoxazole moiety remains in contact with the 
hydrophobic part of N1211. In both mutants however, pleconaril shows strong fluctuations for 
Φ as a result of a loss of surface contacts with N1211, caused by the shift of the βH strand 
(Figure S2B,C). 
A water molecule mediating interactions between the isoxazole nitrogen and the side chains 
of T1094 and R1095 is part of the protein-ligand interaction network in the sensitive virus 
(Figure 4A). Even though in the I1207K mutant pleconaril maintains coordination with a water 
molecule at this position, this variant does not form interactions with R1095. The torsional 
fluctuations of the methylisoxazole add to the instability of the water-mediated interactions 
(Figure S3A). Changes are more significant for the I1207R variant. There, interactions 
mediated by this water molecule are partially replaced by interactions with T1093 (Figure 
S3), which, together with the altered conformation of R1095, cause the conformational shift 
seen for the βC strand. 
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4 Discussion 
For the first time this work characterizes high-level resistance to a CIs of EVs caused by 
I1207K and I1207R substitution. It also confirms single-site substitution of I1092M as a cause 
of high-level resistance (Groarke and Pevear, 1999; Schmidtke et al., 2005). In contrast to 
I1092, I1207 is not part of the ligand binding pocket and confers high-level resistance by an 
unreported molecular mechanism. 
The detected frequency of pleconaril resistance of 1.2 × 10-4 corresponds to previously 
published data for pleconaril-resistant CVB3 (Groarke and Pevear, 1999) and drug-resistant 
mutants of other ssRNA viruses (frequencies reported are between 10-3 and 10-5) (Heinz et 
al., 1989; Stech et al., 1999; Wang et al., 1998). The high mutation rate (Drake et al., 1998; 
Holland et al., 1982) and the existence of quasi species (Domingo, 1992) are caused by (i) 
integration of one mismatched base per 104-105 bases by RNA-dependent RNA polymerase 
of ssRNA viruses and (ii) lack of a proof-reading ability of these enzymes. 
The amino acid substitution I1092M was described earlier by Groarke et al. (Groarke and 
Pevear, 1999), who also detected a CVB3 variant containing two amino acid substitutions, 
I1092L as well as L1207V. However, the impact of the L1207V mutation on the resistant 
phenotype remained unclear. According to the definition of Heinz et al. (Heinz et al., 1989), 
substitutions in I1092 confer high-level resistance (Groarke and Pevear, 1999; Schmidtke et 
al., 2005). This can be explained by the fact that I1092 is one of the 17 amino acids forming 
the hydrophobic pocket of CVB3 (Muckelbauer et al., 1995a). I1092 is situated in the center 
of the pocket and interacts with one of the two methyl groups of pleconaril’s phenyl ring. 
Substitutions of amino acids in the center of the pocket that confer high-level resistance have 
also been reported for rhinoviruses (Badger et al., 1989; Heinz et al., 1989; Ledford et al., 
2005; Ledford et al., 2004; Zhang et al., 2004) and echovirus 11 (Benschop et al., 2015). The 
activity of pleconaril derivatives lacking one or both of the methyl groups of the central phenyl 
ring of pleconaril (Schmidtke et al., 2009) is less affected by the substitution of I1092.  
In contrast to I1092, I1207 is not involved in the formation of the binding pocket 
(Muckelbauer et al., 1995a). Therefore, the observation that mutation of I1207 can lead to a 
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complete loss of drug action is intriguing. MD simulations indicate that substitution of I1207 
by a more bulky, positively charged residue pushes R1095 into the hydrophobic pocket 
toward pleconaril, initiating a cascade of conformational changes that ultimately lead to the 
abolishment of drug action. Importantly, the substitutions appear to not lead to 
conformational rearrangements of the ligand binding site in the apo system, which otherwise 
could completely impair ligand binding. 
The postulated resistance mechanism has similarities with that of influenza virus 
neuraminidase and oseltamivir. Substitution of H274 by a Tyr leads to a substantial loss of 
affinity of oseltamivir for neuraminidase (Wang et al., 2002). The pentanyl substituent of 
oseltamivir forms hydrophobic interactions with the protein. In H274Y variants, the larger Tyr 
pushes the polar side chain of neighboring E276 farther into the binding site, toward the 
hydrophobic pentanyl moiety (Collins et al., 2008). This leads to high-level resistance against 
oseltamivir. In the case of the CVB3 97927 I1207 mutants and pleconaril it is the polar side 
chain of R1095 that is pushed toward the hydrophobic ligand. 
An NCBI database survey with standard nucleotide blast demonstrated a polymorphism at 
position 1092 as well as 1207 in VP1 of CVB3. About 99% of the available CVB3 sequences 
express I1207, three have a V1207 and each one a T1207 or L1207. With respect to 
substitutions at position 1092, 30% of available sequences have isoleucine, 3% leucine and 
67% valine. Thus, viruses with substitutions in position 1092 or 1207 are circulating in nature. 
Obviously, they do not hamper viral replication. This is in good agreement with the results of 
our in vitro studies. Neither antigen expression nor one-step growth curves of CVB3 97927 
and high-level resistant mutants showed any differences. In contrast, attenuated virulence of 
pleconaril-resistant CVB3 with I1092L or I1092M was described in vivo (Groarke and Pevear, 
1999) but highly mouse-pathogenic, pleconaril-resistant CVB3 containing these substitutions 
also exist (Schmidtke et al., 2005; Schmidtke et al., 2007).  
The data presented here underline the vulnerability of the therapeutic efficacy of antivirals 
targeting the hydrophobic pocket of picornaviruses. Knowledge of the key role of residue 
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1207 in CI activity and the new model of a specific resistance mechanism are valuable for 
the rational design of therapeutic agents with superior resistance profiles. 
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Figure captions 
Figure 1. Overview of the two protomers of the CVB3 97927 virus capsid as used for the MD 
simulations. VP1 (purple), VP2 (blue), VP3 (orange), VP4 (cyan). The GH loop and pleconaril are 
green and the second protomer grey. The enlarged section shows VP1 with the location of pleconaril, 
I1092 and I1207. 
 
Figure 2. Replication of wt-CVB3 97927 and three different pleconaril-resistant variants in HeLa 
cells. HeLa cells were infected at a moi of 10 pfu/cell of the respective virus. (A) The influence of 
pleconaril treatment (1 µg/ml) on viral antigen expression was comparatively studied by 
immunohistochemical staining of CVB3-infected HeLa cells 5 h p.i. Virus antigen-positive cells are 
stained in red color. (B) Comparison of single-step life cycles of the selected CVB3 samples. Values 
represent the means and SD of 3 parallel measurements per time point. 
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Figure 3. Backbone RMSD. Development of the backbone RMSD of the (A) complete apo system, 
(B) complete holo system, (C) pocket-forming residues of the apo system and (D) pocket-forming 
residues of the holo system. wt-CVB3 97927 (black), I1207K (orange), I1207R (blue). 
 
Figure 4. Conformational flexibility of VP1 and interactions with pleconaril. (A) In wt-CVB3 
97927, R1095 forms polar interactions with E1105, N1211 and a water molecule. The polar side chain 
of R1095 is hence oriented away from pleconaril toward E1105. (B) In the I1207K mutant, K1207 
forms a salt bridge with E2131 rather than E1105. R1095 points toward the hydrophobic ligand. (C) An 
initially observed salt bridge between R1207 and E1105 in the I1207R mutant is weakened by a 
conformational rearrangement of the βH strand observed during the simulation. In this resistant variant 
the charged side chain of R1095 points deeply into the hydrophobic pocket. (D) B-factors calculated 
for VP1 from the MD trajectories. wt-CVB3 97927 (black), I1207K (orange), I1207R (blue). The 
exposed residues of the GH loop show increased flexibility when compared to the mutants (in 
particular A1200). B-factor plots for VP2, 3 and 4 are provided in Figure S4. 
 
Figure 5. Conformational shifts observed for the βC and βH strands of the wt-CVB3 97927 and 
the two mutants. (A) Representative frame of the wt-CVB3 97927 (grey), I1207K (orange) and 
I1207  (blue) virus strain  selected from the MD trajectories by clustering. (B) Detail of the βH strand 
of the I1207R variant, before (green) and after (blue) the conformational shift. 
 
Figure 6. Conformational shift of the βH-strand induced by the approach of R1095, repelling the 
hydrophobic elements of pleconaril and N1211. (A) RMSD plot of N1211. (B) Distance between the 
aliphatic carbon of the methylisoxazole moiety of pleconaril and the Cα atom of N1211. (C) Distance 
between the guanidino carbon atom of R1095 and the aliphatic carbon of the methylisoxazole group. 
(D) RMSD plot of pleconaril. wt-CVB3 97927 (black), I1207K (orange) and I1207R (blue). 
 
 
Supporting Information 
 
Table S1. Primers used for PCR amplification and sequencing. 
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Table S2. Virus titers determined in one-step replication cycle experiments at different 
hours after infection with CVB3 97-927 variants. 
 
Figure S1. Conformations observed for pleconaril. Representative conformations selected from the 
wt-CVB3 97927 (grey), I1207K (orange) and I1207R (blue) trajectories using an average-linkage 
algorithm for clustering. 
 
Figure S2. Conformational fluctuations of torsion angle Φ of pleconaril. (A) Fluctuations between 
two torsion angle states occur infrequently in the wt-CVB3 97927. They are much stronger for the (B) 
I1207K and (C) I1207R mutants. 
 
Figure S3. Interactions of the isoxazole nitrogen of pleconaril with (A) water and (B) T1093. 
Even though an interaction of pleconaril with a water molecule is maintained in the mutants, the 
interaction network formed is much weaker than that of wt-CVB3 97927 (black). In the I1207R mutant 
(blue) pleconaril is partially switching from an interaction with water to an interaction with T1093. 
 
Figure S4. B-factors calculated for (a) VP2, (b) VP3 and (c) VP4. wt-CVB3 97927 (black), I1207K 
(orange), I1207R (blue). 
Table 1. Influence of amino acid substitutions in position 1092 and 1207 on pleconaril 
susceptibility of CVB3 97927 variants 
CVB3 97927 
n 
1092a 1207a 
plaque reduction 
[%] 
50% inhibitory 
concentration (µg/ml) b 
wt 3 I I 99.99c 0.12 ± 0.09 
variant 1 3 M I no reductiond not active 
variant 2 3 I R no reductiond not active 
variant 3 3 I K no reductiond not active 
a amino acid position in viral protein 1 
b Mean and standard deviation of at least three cytopathic effect inhibition assays. “Not 
active” indicates no inhibition was found after treatment with pleconaril in the non-cytotoxic 
dose range up to 12.5 µg/ml (Makarov et al. 2005).   
c using 1 µg/ml of pleconaril 
d using 8 µg/ml of pleconaril 
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Table 2. Overview of molecular dynamics simulations of the viral protein 1 
CVB3 97927 1092a  1207a state ligand 
wildtype I  I apo none 
variant 2 I  R apo none 
variant 3 I  K apo none 
wildtype I  I holo pleconaril 
variant 2 I  R holo pleconaril 
variant 3 I  K holo pleconaril 
a  amino acid position in viral protein 1 
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